Fig. 5.

Increased RA severity by p53 inhibition in PARK2-deficient mice. Mice were injected with anti-type II collagen antibody on day 0, followed by LPS and p53 inhibitor treatment on day 3. Control mice were not treated with p53 inhibitor. (A) Development of CAIA was monitored for 21 days as described in the legend for Fig. 1. (B, C) iNOS and COX-2 expression, as determined by immunohistochemistry. (D) P53 expression in joint tissue from mice with CAIA. β-Actin and histone served as loading controls. (E) Serum IL-1β, IL-6, and TNF-α levels, as measured by ELISA. Values represent mean±SD from five mice. *P<0.05 vs. PARK2 KO mice with CAIA and LPS. (F) DNA binding activity of NF-κB, as determined by electrophoretic mobility shift assay. Each band in the blots is representative of three experiments.